Impact and Adoption of Momelotinib in Myelofibrosis

EP: 1.Myelofibrosis Care: Pharmacist Role and Treatment Challenges

EP: 2.Blood Shortages Impacting Myelofibrosis Care

EP: 3.Challenges in Myelofibrosis: Red Blood Cell Transfusion Shortages

Now Viewing

EP: 4.Impact and Adoption of Momelotinib in Myelofibrosis

EP: 5.Emerging Therapies and Momelotinib Impact

EP: 6.Inpatient to Outpatient: Myelofibrosis Care

EP: 7.Challenges in Outpatient Transition For Myelofibrosis Care

EP: 8.Navigating Myelofibrosis Transitions

EP: 9.Pharmacist-Led Patient Education Strategies

EP: 10.Addressing Socioeconomic Barriers in Myelofibrosis Care

EP: 11.Patient Advocacy in Myelofibrosis Care

EP: 12.Tailoring Myelofibrosis Care: Patient Preferences and Challenges

EP: 13.Advancements in Myelofibrosis Care: Pharmacists' Perspectives

This is a video synopsis/summary of a Peer Exchange involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; Shawn Griffin, PharmD, BCOP; and Robert Mancini, PharmD, BCOP, FHOPA.

In this Pharmacy Times® Peer Exchange, led by Mahmoudjafari, Nachar discusses the MOMENTUM trial, highlighting momelotinib’s efficacy in reducing symptoms and achieving transfusion independence in myelofibrosis patients. Griffin emphasizes momelotinib’s inclusion in National Comprehensive Cancer Network guidelines and envisions its role in treating severely symptomatic anemia. The speakers agree on the use of momelotinib for patients receiving Janus kinase inhibitors and those in rural settings facing access challenges. Davis praises momelotinib’s approval and its potential to reduce transfusions amid shortages. The discussion also touches on emerging therapies and research advancements in myelofibrosis.

This summary was AI-generated and reviewed by Pharmacy Times^® editorial staff.